Status:
COMPLETED
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is the examine the effect of taking exenatide on the blood levels (pharmacokinetics) of orally-administered contraceptives.
Eligibility Criteria
Inclusion
- Pre-menopausal female of child-bearing potential.
- Body Mass Index (BMI) between 19 and 35 kg/m\^2, inclusive.
Exclusion
- On implanted contraceptives for 6 months, or injectable contraceptives for 12 months prior to the study.
- Evidence of diabetes mellitus.
- Participation in a study involving administration of an investigational compound within the past 3 months.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00254800
Start Date
November 1 2005
End Date
August 1 2006
Last Update
August 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Plymouth, United Kingdom